Home  >  News
Eppen_Himac_Jan25
Waters_Ebook_Dec24
you can get e-magazine links on WhatsApp. Click here
Clinical Trials + Font Resize -

Senhwa Biosciences seeks US FDA nod for phase I/II study of Silmitasertib in combo with chemotherapy in children and young adults with relapsed refractory solid tumours

Taipei, Taiwan
Saturday, July 13, 2024, 18:00 Hrs  [IST]

Senhwa Biosciences, Inc., announced IND Submission to US FDA for the phase I/II study of Silmitasertib (CX-4945) in combination with chemotherapy in children and young adults with relapsed refractory solid tumours. This investigator-initiated trial (IIT) will be conducted by the Penn State Health Children’s Hospital and the prestigious Beat Childhood Cancer Research Consortium, a group of over 50 universities and children's hospitals, based at Penn State College of Medicine in Hershey, Pa., that offers a worldwide network of paediatric cancer clinical trials. The funding is sponsored by the Four Diamonds Foundation, with Senhwa Biosciences providing the investigational drug, Silmitasertib (CX-4945).

The clinical trial is conducted in two phases: the first phase focuses on establishing the safety and dosage of Silmitasertib (CX-4945) in paediatric patients with relapsed or refractory solid tumours, while the second phase evaluates its efficacy and potential as a novel treatment option.

As high CK2 activity is noted across several paediatric cancers, including neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, osteosarcoma, medulloblastoma, and liposarcoma. Recent study has shown that CK2 is one of the key kinases that is essential for maintaining the stabilization of MYCN protein, the oncogenic driver in neuroblastoma. In view of the anti-tumour activity of CK2 inhibitor, the Beat Childhood Cancer Research Consortium at The Pennsylvania State University regards Silmitasertib (CX-4945) high therapeutic potential of treating paediatric cancers.

Neuroblastoma is the most common type of solid malignant tumour in children, aside from brain tumours and lymphomas. Over 90% of cases are diagnosed before the age of 5. 70% of patients already have metastatic disease by the time symptoms appear, and the 20-year survival rate is only around 30%. In the US, there are 700-800 new cases each year, accounting for about 6% of childhood cancers, meeting the definition of a rare disease.

Senhwa Biosciences is planning to apply for Orphan Drug Designation (ODD) and Rare Paediatric Disease Designation (RPD) for Silmitasertib (CX-4945) for the treatment of neuroblastoma. If these designations are granted and the drug is successfully commercialized, the company would obtain a Priority Review Voucher (PRV). The holder of a PRV can designate any future human drug application to receive priority review, potentially shortening the review time to 6 months, which could accelerate the timeline for the company (or its partners) to bring other products to market.

The clinical trial design also includes Ewing's sarcoma and osteosarcoma, which are common paediatric bone cancers with poor prognoses, representing unmet medical needs.

Senhwa Biosciences Inc. was established in 2012 and listed on the Taipei Exchange on April 24, 2017. The company aims to transform the model for new drug development by focusing on human efficacy.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
Asia_Lab_Expo2025
chemexpoindia
Copyright © 2024 Saffron Media Pvt. Ltd | twitter
 
linkedin
 
 
linkedin
 
instagram